

Aimovig - Mode of action - HCP

[Prescribing information](#)

Image



Image



Aimovig® (erenumab) mode of action

Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.¹

Aimovig is specifically designed to stop migraine before it starts^{2,3}

Play the Aimovig mechanism of action video below to see how it is believed to work in

migraine.

Aimovig® (erenumab)

Mechanism of Action

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report,
or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month¹

This video contains promotional content and has been developed and funded by Novartis Pharmaceuticals UK, intended for UK healthcare professionals only.


Prescribing information for Aimovig can be found on the web page where this video is hosted.

1. Aimovig® (erenumab) Summary of Product Characteristics.

VIDEO


Aimovig is the first licensed CGRP receptor antagonist in the UK, specifically designed to prevent migraine across the spectrum^{*1,4}

Image



Aimovig is 100% human and binds potently and selectively to the CGRP receptor, blocking its activation¹

Image



Your guide to Aimovig

PDF

[Download](#)

Your guide to Aimovig

A guide for patients prescribed Aimovig to provide them with important information about what Aimovig is, who it is for, how it works and what to expect during treatment.



Video

6 mins 50 secs

Aimovig injection training video

Video - 10 Jul 2024

6 mins 50 secs

Aimovig injection training video

[See more details](#)

Hide details

CGRP, calcitonin gene related peptide; Ig, immunoglobulin.

References

1. Aimovig® (erenumab) Summary of Product Characteristics.
2. Aimovig Core Data Sheet v2.5.
3. Garg S, et al. *Anaesthesiology* 2020;36(1):104–109.

4. Bigal ME, et al. *Headache* 2013;53(8):1230-1244.



Dosing and administration

Dosing and administration

See more details

Hide details



Safety profile

Safety profile

See more details

Hide details

UK | March 2025 | FA-11330943

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/neuroscience/aimovig/mode-of-action>